Q-omics provides the consensus-scored TRAJ26 profile across patient tissues and cancer cell-line models. TRAJ26 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TRAJ26 is differentially expressed in 3, with the highest sampling consensus in STAD. Additionally, TRAJ26 RNA expression shows 11,881 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, STAD, and LSCC as cancer lineages where TRAJ26 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRAJ26 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRAJ26 survival associations across molecular data types. TRAJ26 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRAJ26 RNA expression–survival associations across cancer types. High TRAJ26 expression shows unfavorable associations in LGG, KICH, BLCA, LUSC and THCA, but favorable associations in HNSC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .006). Together, the overview and detailed table identify HNSC as the clearest survival context for TRAJ26 RNA expression.
This table summarizes TRAJ26 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for TRAJ26. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRAJ26 shows higher tumor expression in STAD, BRCA and KIRC. The STAD box plot shows higher TRAJ26 RNA expression in tumor versus normal tissue (log2 FC = +0.422, t-test p = .002).
This table shows molecular features associated with TRAJ26 in patient tissues and cancer cell lines. In patient samples, TRAJ26 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
